Alcohol–Endocannabinoid Reviews Need to Keep Stages of Dependence Separate

A 2012 review organized alcohol–endocannabinoid research around changes occurring at different stages of dependence. A finding during repeated exposure should not automatically be assigned to withdrawal or renewed drug seeking.

The evidence spanned different experimental settings

The synthesis combined behavioral studies with in-vitro and ex-vivo findings involving endocannabinoid levels and CB1 function. These approaches examine different parts of a proposed mechanism. A cellular response cannot independently establish motivation to consume alcohol.

The behavioral question was also specific

The review described cannabinoid-system contributions to alcohol's reinforcing and motivational properties. Reinforcement, physical tolerance and withdrawal are distinct outcomes. Evidence involving one cannot be relabeled as proof of all the others simply because the same receptor system is implicated.

Stage and sampling define the inference

A measured receptor or transmitter change needs an exposure history and observation time. The review's stage-based framework helps prevent a single snapshot from being treated as the permanent state of the system. It does not establish one biomarker for every phase of dependence.

Interpreting the evidence

This historical synthesis supports recording whether evidence concerns ongoing exposure, adaptation, withdrawal or motivation. It does not demonstrate that cannabis treats alcohol dependence or that a cannabinoid-system observation can determine an individual's stage of illness.

Related reading: interpreting cannabis tolerance claims.

Research reference

Pava MJ; Woodward JJ (2012). A review of the interactions between alcohol and the endocannabinoid system: implications for alcohol dependence and future directions for research. Alcohol (Fayetteville, N.Y.). doi:10.1016/j.alcohol.2012.01.002.

This analysis draws on the supplied review abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

ABHD6 Inhibition After Brain Injury Improved Several Outcomes in Mice Without Testing THC Treatment

Post-injury treatment with the ABHD6 inhibitor WWL70 improved motor, memory and tissue outcomes in a mouse traumatic-brain-injury model. The study investigated endogenous 2-AG signaling, rather than administering THC or testing marijuana as a treatment. A different breakdown enzyme was the intervention target ABHD6 contributes a smaller portion of 2-AG hydrolysis…

Spread the love

Read Article: ABHD6 Inhibition After Brain Injury Improved Several Outcomes in Mice Without Testing THC Treatment

Clonidine Pretreatment Reduced WIN Sensitivity Without Producing the Same Clonidine Tolerance in Isolated Ileum

Clonidine exposure reduced later sensitivity to WIN 55,212-2 in isolated guinea-pig ileum even though the tested clonidine incubations did not produce tolerance to clonidine's own effect. Cross-desensitization and within-drug tolerance were separable observations. Both drugs initially inhibited stimulated contractions The study used electrically evoked twitches in an organ-bath preparation. WIN,…

Spread the love

Read Article: Clonidine Pretreatment Reduced WIN Sensitivity Without Producing the Same Clonidine Tolerance in Isolated Ileum

URB597 Changed Morphine Tolerance and Passive-Avoidance Learning in Rats

A rat study found that URB597 prevented the tested development of morphine antinociceptive tolerance and alleviated morphine-related impairment on a passive-avoidance learning task. These were two separately measured outcomes of an endocannabinoid-enzyme intervention. Repeated morphine established the adaptation question The investigators administered morphine repeatedly and gave URB597 beforehand. Tolerance was…

Spread the love

Read Article: URB597 Changed Morphine Tolerance and Passive-Avoidance Learning in Rats

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us